
Recent Trend and Development in Pharmaceutical Industry


Richard Hu, Associate Director CMC, Curis
In our exciting and ever-changing industry, pharmaceutical and biotech companies must continue innovating not only their technologies but also the way they do business. Let’s review the top three trends that are “hot” in the eyes of a formulation scientist.
For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game
The first thing that came to mind is the advancement of CRISPR/Cas9, a gene editing technology developed by Professor Zhang at MIT. Inspired by how living cells disable invading viruses, CRISPR (Clustered Regularly Short Palindromic Repeats) technology utilizes Cas9, a nuclease enzyme, to cut DNA strands at a precise location when the target gene is complexed with a guide-RNA. As a result, scientists can disable certain sequence in that gene and understand the function of that particular sequence. Sequentially, CRISPR also enables scientists to add a desired function to the gene by inserting a pre-fabricated sequence. We all know that genes define who we are as life-forms and individuals. There is no doubt that our genes have a profound effect on our health. While still in its infancy, gene editing certainly has the potential to completely transform not only our industry but our world as well. If something can finally bankrupt our social security, I think gene editing will be it.
For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game. In this new hope, scientists are developing drugs that can stimulate our own immune system to recognize and fight cancerous cells. One such advancement is the chimeric antigen receptor (CAR) T-cell technology, in which a patient’s own immune cells are removed, engineered to have the ability to recognize and attack cancerous cells, then infused back to his/her body to fight cancer. While only approved to treat limited types of cancer and may have severe side effects, the approval of Kymriah® and Yescarta® clearly represents the future of personalized medicine. Another trend worth mentioning in immunotherapy is the advancement of checkpoint inhibitor. These drugs are often highly targeted, highly efficient and have relatively low side effects. In recent years, antibody-based checkpoint inhibitors have dramatically improved the management of cancer. To me, developing small molecule version of such inhibitors, which are orally available and going to be much cheaper, is even more exciting.
In the foreseeable future, biopharmaceutical companies, regardless of their sizes, will continue to utilize R&D outsourcing to access innovations and expertise. According to Visiongain, the global drug discovery outsourcing market is expected to exceed $40 billion by 2026. Meanwhile, the tide of outsourcing model is certainly shifting, especially at early stage. R&D work is coming back to the States, while some companies start to run clinical trials in developing countries, often-times looking for treatment-naïve patients. I also sense a strong focus from pharmaceutical companies on partnering with academia. In the past few years, several major pharma companies moved their R&D headquarters into the most congested neighborhoods in Boston, with the intention to put their folks into the proximity of Harvard and MIT. But for God’s sake, put them in the suburb and take a subway to the “Inspiration” when needed. Haven’t they checked out the Boston morning traffic in last twenty years?
CIOReview Client : Flagship
Check Out Review Of CIOReview : Crunchbase, Glassdoor
Check This Out : CIOReview Overview, Muckrack
ON THE DECK
Featured Vendors
Tenthpin: The Trusted Advisor for Data-Driven Patient- Centric Value Chain Management in Life Sciences
Process Stream: Into the Depths: How Process Stream Leverages Experience and Embedded Research to Transform Businesses from the Inside Out
Indegene: Leveraging Technology to Drive Growth and Productivity Investing In Innovation In Operations, Analytics and Clinical Technology
MMIS: Global Compliance Platform Streamlines Processes and Delivers Business Intelligence Enterprise-Wide
Acceliant: Leading with Innovation, Facilitating Collaboration, Standardization and Productivity in Clinical Trial Management
Saama Technologies: New Fluid Analytics Engine from Saama Cost-Effectively and Rapidly Resolves Complex Data Analytics Challenges for Life Sciences
Iris Interactive Corporation: Boosting Collaboration and Decision Making Processes to Bring Products
Techsol Corporation: Offering Domain Rich, Regulatory Compliant, Accelerated and Cloud Enabled Techn
Solea Software Solutions: Offering Business Intelligence, Analytics, and Portal Services for Flouris
Xybion Corporation: Providing Interconnected Technology Enabled Solutions for Life Sciences, and other Highly Regulated Industries
EDITOR'S PICK
Essential Technology Elements Necessary To Enable...
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
Comparative Data Among Physician Peers
By George Evans, CIO, Singing River Health System
Monitoring Technologies Without Human Intervention
By John Kamin, EVP and CIO, Old National Bancorp
Unlocking the Value of Connected Cars
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
Digital Innovation Giving Rise to New Capabilities
By Gregory Morrison, SVP & CIO, Cox Enterprises
Staying Connected to Organizational Priorities is Vital...
By Alberto Ruocco, CIO, American Electric Power
Comprehensible Distribution of Training and Information...
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
The Current Focus is On Comprehensive Solutions
By Sergey Cherkasov, CIO, PhosAgro
Big Data Analytics and Its Impact on the Supply Chain
By Pascal Becotte, MD-Global Supply Chain Practice for the...
Technology's Impact on Field Services
By Stephen Caulfield, Executive Director, Global Field...
Carmax, the Automobile Business with IT at the Core
By Shamim Mohammad, SVP & CIO, CarMax
The CIO's role in rethinking the scope of EPM for...
By Ronald Seymore, Managing Director, Enterprise Performance...
Driving Insurance Agent Productivity with Mobile and Big...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
Transformative Impact On The IT Landscape
By Jim Whitehurst, CEO, Red Hat
Get Ready for an IT Renaissance: Brought to You by Big...
By Clark Golestani, EVP and CIO, Merck
Four Initiatives Driving ECM Innovation
By Scott Craig, Vice President of Product Marketing, Lexmark...
Technology to Leverage and Enable
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
AI is the New UI-AI + UX + DesignOps
By Amit Bahree, Executive, Global Technology and Innovation,...
Evolving Role of the CIO - Enabling Business Execution...
By Greg Tacchetti, CIO, State Auto Insurance
Read Also
What It Truly Means For IT Security To Bea Business Enabler
Digital Transformation 2 Requires a CIO v2.x
Leverage ChatGPT the Right Way through Well-Designed Prompts
Water Strategies for Climate Adaption
Policy is a Key Solution to Stopping Packaging Waste
Congestion-Driven Basis Risk, A Challenge for the Development of...
